MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
aditxt notes related...
$2,425K
Borrowings under
short-term debt
$383K
Net restricted cash
and cash...
$1,891K
Canceled cashflow
$917K
Net change in
restricted cash and cash...
-$163K
Canceled cashflow
$1,891K
Accrued expenses and
other liabilities
$4,468K
Noncash interest
expense
$2,366K
Inventory write-down for
excess & obsolescence...
$1,012K
Amortization of intangible
asset
$499K
Net income (loss)
$391K
Change in fair value of
financial instruments
-$359K
Prepaid and other assets
-$356K
Accounts payable
$182K
Stock-based compensation
$166K
Noncash right-of-use
asset amortization
$108K
Loss on contingent
liability
$54K
Net loss on disposal
or impairment of...
-$20K
Depreciation
$19K
Payments under
short-term debt and notes ...
$905K
Cash paid for
financing costs
$12K
Net restricted cash
and cash...
-$1,992K
Canceled cashflow
$10,000K
Net restricted cash
and cash...
-$62K
Gain on accounts
payable and accrued...
$5,636K
Trade accounts
receivable
$2,648K
Gain on change in
accounting estimates on...
$1,933K
Accrued compensation
-$907K
Contingent liabilities
-$499K
Inventories
$260K
Operating lease
liabilities
-$109K
Payments related to
intangible asset...
$57K
Purchases of property and
equipment
$5K
Back
Back
Cash Flow
source: myfinsight.com
Evofem Biosciences, Inc. (EVFM)
Evofem Biosciences, Inc. (EVFM)